These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

161 related items for PubMed ID: 7851482

  • 1. Enhancement of thrombolytic efficacy of tissue-type plasminogen activator by adjuvants in the guinea pig thrombosis model.
    Nishiyama H, Umemura K, Saniabadi AR, Takiguchi Y, Uematsu T, Nakashima M.
    Eur J Pharmacol; 1994 Oct 24; 264(2):191-8. PubMed ID: 7851482
    [Abstract] [Full Text] [Related]

  • 2. Effects of vapiprost, a novel thromboxane receptor antagonist, on thrombus formation and vascular patency after thrombolysis by tissue-type plasminogen activator.
    Matsuno H, Uematsu T, Umemura K, Takiguchi Y, Wada K, Nakashima M.
    Br J Pharmacol; 1992 Jul 24; 106(3):533-8. PubMed ID: 1387025
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. In vivo thrombin inhibition enhances and sustains arterial recanalization with recombinant tissue-type plasminogen activator.
    Jang IK, Gold HK, Leinbach RC, Fallon JT, Collen D.
    Circ Res; 1990 Dec 24; 67(6):1552-61. PubMed ID: 2123135
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Role of thrombin and thromboxane A2 in reocclusion following coronary thrombolysis with tissue-type plasminogen activator.
    Fitzgerald DJ, Fitzgerald GA.
    Proc Natl Acad Sci U S A; 1989 Oct 24; 86(19):7585-9. PubMed ID: 2508092
    [Abstract] [Full Text] [Related]

  • 8. Inhibitory effect of clopidogrel, vapiprost and argatroban on the middle cerebral artery thrombosis in the rat.
    Umemura K, Kawai H, Ishihara H, Nakashima M.
    Jpn J Pharmacol; 1995 Mar 24; 67(3):253-8. PubMed ID: 7630043
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Combination of inhibition of thrombin and blockade of thromboxane A2 synthetase and receptors enhances thrombolysis and delays reocclusion in canine coronary arteries.
    Yao SK, Ober JC, Ferguson JJ, Anderson HV, Maraganore J, Buja LM, Willerson JT.
    Circulation; 1992 Dec 24; 86(6):1993-9. PubMed ID: 1451271
    [Abstract] [Full Text] [Related]

  • 11. Inhibitory effect of a novel orally active GP IIb/IIIa inhibitor, SC-54684A on intimal thickening in the guinea pig femoral artery.
    Umemura K, Nishiyama H, Kikuchi S, Kondo K, Nakashima M.
    Thromb Haemost; 1996 Nov 24; 76(5):799-806. PubMed ID: 8950793
    [Abstract] [Full Text] [Related]

  • 12. Comparative effects of aspirin, a synthetic thrombin inhibitor and a monoclonal antiplatelet glycoprotein IIb/IIIa antibody on coronary artery reperfusion, reocclusion and bleeding with recombinant tissue-type plasminogen activator in a canine preparation.
    Yasuda T, Gold HK, Yaoita H, Leinbach RC, Guerrero JL, Jang IK, Holt R, Fallon JT, Collen D.
    J Am Coll Cardiol; 1990 Sep 24; 16(3):714-22. PubMed ID: 2117620
    [Abstract] [Full Text] [Related]

  • 13. Evaluation of the combination of a tissue-type plasminogen activator, SUN9216, and a thromboxane A2 receptor antagonist, vapiprost, in a rat middle cerebral artery thrombosis model.
    Umemura K, Wada K, Uematsu T, Nakashima M.
    Stroke; 1993 Jul 24; 24(7):1077-81; discussion 1081-2. PubMed ID: 8322383
    [Abstract] [Full Text] [Related]

  • 14. Arterial thrombosis model with photochemical reaction in guinea-pig and its property.
    Takiguchi Y, Hirata Y, Wada K, Nakashima M.
    Thromb Res; 1992 Aug 15; 67(4):435-45. PubMed ID: 1412222
    [Abstract] [Full Text] [Related]

  • 15. Roles of platelet-activating factor, thromboxane A2, ADP and thrombin in thrombogenesis in the guinea pig.
    Hirata Y, Takiguchi Y, Wada K, Matsuno H, Umemura K, Uematsu T, Nakashima M.
    Eur J Pharmacol; 1993 Feb 16; 231(3):421-5. PubMed ID: 8449234
    [Abstract] [Full Text] [Related]

  • 16. A thrombosis model for evaluating thrombolytic agents in the guinea-pig: comparison of t-PA, scu-PA and a novel thrombolytic agent, staphylokinase, on thrombolytic activity.
    Hirata Y, Umemura K, Takiguchi Y, Uematsu T, Nakashima M.
    Blood Coagul Fibrinolysis; 1993 Aug 16; 4(4):569-75. PubMed ID: 7692999
    [Abstract] [Full Text] [Related]

  • 17. Thrombolysis of canine femoral artery thrombus by a novel modified tissue-type plasminogen activator (E6010).
    Suzuki N, Suzuki S, Nagaoka N, Mizuo H, Yuzuriha T, Yoshitake S, Kanmatuse K.
    Jpn J Pharmacol; 1994 Jul 16; 65(3):257-63. PubMed ID: 7799526
    [Abstract] [Full Text] [Related]

  • 18. Comparative thrombolytic properties of tissue-type plasminogen activator and of a plasminogen activator inhibitor-1-resistant glycosylation variant, in a combined arterial and venous thrombosis model in the dog.
    Collen D, Stassen JM, Yasuda T, Refino C, Paoni N, Keyt B, Roskams T, Guerrero JL, Lijnen HR, Gold HK.
    Thromb Haemost; 1994 Jul 16; 72(1):98-104. PubMed ID: 7974384
    [Abstract] [Full Text] [Related]

  • 19. Comparison of enoxaparin, hirulog, and heparin as adjunctive antithrombotic therapy during thrombolysis with rtPA in the stenosed canine coronary artery.
    Leadley RJ, Kasiewski CJ, Bostwick JS, Bentley R, McVey MJ, White FJ, Perrone MH, Dunwiddie CT.
    Thromb Haemost; 1997 Oct 16; 78(4):1278-85. PubMed ID: 9364998
    [Abstract] [Full Text] [Related]

  • 20. Thrombolytic and haemorrhagic effects of bolus doses of tissue-type plasminogen activator and a hybrid plasminogen activator with prolonged plasma half-life (K2tu-PA: CGP 42935).
    Agnelli G, Pascucci C, Nenci GG, Mele A, Bürgi R, Heim J.
    Thromb Haemost; 1993 Aug 02; 70(2):294-300. PubMed ID: 8236138
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.